The following important news was reported on the BSD Medical SI board, but it has significance beyond the news release. The NR was about a single product (product line, actually), while it is just one successful application of an emerging therapy that rivals the mainline cancer therapies of surgery, radiotherapy, and chemotherapy. And, some strong arguments can be made that this new therapy (under development for decades, during many successful medical trials) is substantially more important than the other three! (because it also strongly enhances those other three when used as an adjuvant).
http://investor.bsdmedical.com/press-release/sales/bsd-medical-reports-significant-growth-microthermx-microwave-ablation-system-sal
". . . announced today a 391% increase in sales for the MicroThermX® Microwave Ablation System (MicroThermX®) product line for September 2012, as compared to September 2011. Disposable SynchroWave antennas were a significant portion of these sales, reflecting the success of the Company's fee-per-use."
The strong success of the “FPU” plan was clearly, unequivocally revealed in the 7 Aug Webinar (replay still available at the company’s website). The above news release was to announce that the success was still continuing in September (no surprise!). We will hear yet more about this ongoing success in the 10K due in mid November, which will surely include some "subsequent events" discussion. And, rapidly expanding MTX-180 use can be expected to continue for years, as it has been proven safer and more effective than the present Interventional Oncology (IO) leader, radio-frequency ablation (RFA). Further, the advantage over RFA (which itself has advantages over ultrasound and cryogenic therapies) is FUNDAMENTAL. BSD M's microwave ablation (MWA) has overwhelming prospects for IO! And, their other microwave-based products have similar prospects, or more.
Precise, versatile microwave heating is a revolution in cancer therapy!!! And, BSD Medical is the world leader in the technology. |
